{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-24-000061","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2024-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.875088+00:00","generated_at":"2026-06-01T16:55:46.405760+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Senti Bio appoints Kanya Rajangam as President; CEO Lu remains CEO","bullets":["Tim Lu stepped down as President effective May 14, 2024, but continues as CEO.","Kanya Rajangam, M.D., Ph.D., appointed President; she remains Head of R&D and CMO.","Rajangam joined Senti in July 2022; prior CMO at Nkarta (NKTX) and Atara (ATRA).","Her compensation includes $490K base salary, 40% target bonus, option grant, and severance per 2022 offer letter."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-24-000061","json":"https://secwatch.observer/filing/0001854270-24-000061.json","markdown":"https://secwatch.observer/filing/0001854270-24-000061.md","text":"https://secwatch.observer/filing/0001854270-24-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000061/0001854270-24-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000061/snti-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T16:55:46.405760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4426862dff","claim":"Kanya Rajangam was appointed as President at Senti Biosciences, Inc..","evidence_excerpt":"Kanya Rajangam, M.D., Ph.D., the Company's Head of Research and Development, and Chief Medical Officer, was appointed to serve as the President of the Company, effective as of May 14, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000061/0001854270-24-000061-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}]},{"claim_id":"a051305eda","claim":"Timothy Lu changed role as President at Senti Biosciences, Inc..","evidence_excerpt":"Timothy Lu, M.D., Ph.D., Chief Executive Officer and President, stepped down as President","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000061/0001854270-24-000061-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"President"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}